Loading...
Loading...
ALNY| Name | Value |
|---|---|
| Revenues | 420.1M |
| Cost of Revenue | 3.9M |
| Gross Profit | 416.2M |
| Operating Expense | 573.9M |
| Operating I/L | -76.9M |
| Other Income/Expense | -31.8M |
| Interest Income | 32.1M |
| Pretax | -108.7M |
| Income Tax Expense | -2.9M |
| Net Income/Loss | -111.6M |
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company specializing in RNA interference therapeutics. The company's revenue is generated through the development and commercialization of RNAi-based drugs for genetic, cardio-metabolic, hepatic infectious, and CNS/ocular diseases. Marketed products include ONPATTRO, GIVLAARI, and OXLUMO, targeting specific conditions such as hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria. Alnylam also has a robust pipeline of investigational RNAi therapeutics, including treatments for chronic HBV infection, hypertension, and rare diseases like hemophilia. The company's strategic collaborations with industry leaders further contribute to its revenue streams.
